Tobacco Product Susceptibility and Substitutability by Rurality and Alcohol Use
Launched by MARK J RZESZUTEK, PHD · May 29, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying how living in rural areas and alcohol use may affect people's chances of starting or stopping tobacco products, like cigarettes and e-cigarettes. Researchers want to understand how these factors influence people's interest in new tobacco products and their likelihood of switching to products that help them quit smoking. They will look at different types of tobacco products, including those with high and low levels of nicotine, and see how people respond to them.
To participate, you need to be at least 21 years old and live in the USA. There are different groups in the study: one for people who smoke or use e-cigarettes frequently, another for those who haven't used tobacco products in the past month, and two groups based on alcohol use. If you’re interested, the study will involve some assessments and surveys about your tobacco and alcohol use, but you won’t be required to change your habits. This research is important because it aims to better understand how to help people, especially in rural areas, reduce their tobacco use.
Gender
ALL
Eligibility criteria
- • Cigarette/E-Cigarette Users
- Inclusion Criteria:
- • 21 years of age or older
- • Smoke cigarettes or use e-cigarettes 25 or more days a month
- • Cigarette/E-Cigarette Non-Users
- Inclusion Criteria:
- • 21 years of age or older
- • Do not report using an e-cigarette or cigarette in the past month
- • Risky Alcohol Users
- Inclusion Criteria:
- • 21 years of age or older
- • A score of 8 or higher on the Alcohol Use Disorder Identification Test
- • Non-Risky Alcohol Users
- Inclusion Criteria:
- • 21 years of age or older
- • A score of 7 or lower on the Alcohol Use Disorder Identification Test
- • All groups
- Inclusion Criteria:
- • Located in the USA
- • At least 100 complete studies on Prolific
- Exclusion Critera:
- • Failing attention checks during the screener
About Mark J Rzeszutek, Phd
Mark J. Rzeszutek, PhD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a strong background in biomedical sciences and extensive experience in trial design and implementation, Dr. Rzeszutek leads innovative studies that focus on the development of novel therapeutics and treatment strategies. His expertise encompasses various therapeutic areas, and he is dedicated to ensuring rigorous ethical standards and regulatory compliance throughout the research process. Dr. Rzeszutek's collaborative approach fosters partnerships with academic institutions and industry leaders, driving forward the mission to translate scientific discoveries into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported